Novavax, the American biotechnology company, announced that its Covid-19 vaccine is 100% effective in preventing the disease.
The vaccine has an overall efficacy of 90.4%.
The company’s phase three trials for their Covid-19 vaccine involved 29,960 adults across 113 sites in the United States and six sites in Mexico provided the encouraging results.
Of those who received a vaccine in the trial, only 14 cases of coronavirus were detected and Novavax has said that all of the cases resulted in a mild illness.
US health officials have given one dose of a coronavirus vaccine to 53% of the total population and of those who have fully vaccinated 43.4% of Americans, according to the Centers for Control Disease and Prevention (CDC).
In total, since January, 309 million doses have been administered across the States.
[embedpost slug=”what-are-the-impacts-of-the-sinovac-covid-19-vaccine/”]
